Vinati Organics rallies aggressively by 10.88% on robust Q4 and FY22 results
Last Updated: 16th May 2022 - 05:58 pm
The company witnessed a growth of over 69% in revenues for FY22.
Vinati Organics Ltd, an S&P BSE 100 company primarily engaged in manufacturing pharmaceuticals drugs, has been trending on Dalal Street as it has rallied by about 1.26% amid a falling market from its previous close of Rs 926.25. The scrip opened at Rs 890 and made a day’s high of Rs 942.50.
The company announced its Q4 and FY22 results on 14th May. In Q4FY22, revenue grew by 73.75% YoY to Rs 486.09 crore from Rs 279.77 crore in Q4FY21. On a sequential basis, the top-line was up by 31.75%. PBIDT (Ex OI) was reported at Rs 138.78 crore, up by 40.01% as compared to the year-ago period and the corresponding margin was reported at 28.55%, contracting by 688 basis points YoY. PAT was reported at Rs 101.1 crore, up by 42.7% from Rs 70.85 crore in the same quarter of the previous fiscal year. The PAT margin stood at 20.8% in Q4FY22 contracting from 25.32% in Q4FY21.
As far as the fiscal 2022 results are concerned, the revenues grew by 69.3% to Rs 1,615.5 crore as against FY21. The EBITDA and PAT increased by 30.6% and 28.7% to Rs 495 crore and Rs 346.6 crore, respectively. The stock witnessed a gap up of 2.7% and remained buoyant throughout the day.
Vinati Organics Limited, established in 1989, is a speciality chemical company, focusing on manufacturing speciality chemicals and organic intermediaries. The company has two plants, and both are situated in Maharashtra at Mahad (Raigad) and Lote Parashuram (Ratnagiri). The company is world leader in two of its main products, Isobutyl Benzene (IBB) and 2-Acrylamido 2 Methylpropane Sulfonic Acid (ATBS). The company is present in over 22 countries worldwide and exports products to customers across the US, Europe and Asia. The stock has a 52-week high of Rs 4,986.85 and a 52-week low of Rs 1,926.
Trending on 5paisa
Discover more of what matters to you.
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.